VLA 0.00% $1.75 viralytics limited

Ann: Viralytics to Present New CAVATAK Clinical Data at AACR, page-6

  1. 1,172 Posts.
    lightbulb Created with Sketch. 71
    There will always be sellers... different people...different lives... different circumstances.
    Maybe selling VLA to sink into something else anticipated to rocket in the very near term, with the intention to re-enter VLA (time frames usually thwart these plans... market doesn't behave the way one would like).
    Perhaps not as knowledgeable as we long suffering holders ( although I can think of worse ways to have suffered).
    Anyway... to each his own!!
    Personally I cannot possibly imagine "news from the podium" being anything but in keeping with VLA's past presentation history.... it will simply be a case of degree.
    Sleep well, good people.
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.